Hyundai Bioscience
Manufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3f 150 Bukahyeon-ro Seodaemun-gu, Seoul,...Website
www.hyundaibioscience.comRevenue
$7.1 MillionStock Symbol
48410Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hyundai Bioscience
HYUNDAI BIOSCIENCE is a specialized biotechnology company focused on drug delivery system (DDS) technologies. They offer innovative and efficient solutions based on accumulated research and advanced bio-technology, targeting various medical conditions including cancer and viral infections. Their product lineup includes XAFTY, a broad-spectrum antiviral, and PENETRIUM, a treatment aimed at overcoming drug resistance. The company serves clients in the healthcare and cosmetic sectors, emphasizing scientific innovation and responsible practices to enhance human health.Explore more
Popular SearchesHyundai Bioscience CorpHyundai BioscienceBioscience CorpSIC Code 28,283NAICS Code 32,325Ticker KOSDAQ: 48410Show moreHyundai Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hyundai Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Hyundai Bioscience
Hyundai Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Hyundai Bioscience recently announced quarterly report
Check out if Hyundai Bioscience is spiking on competitors!
Check if Hyundai Bioscience has recently received funding, and reach out quickly before it becomes old news!
Click to see if Hyundai Bioscience had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Hyundai Bioscience launches new products
Funding: Get notified immidiatlly once Hyundai Bioscience has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Hyundai Bioscience
Compare insights from companies similar to Hyundai Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hyundai Bioscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hyundai Bioscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hyundai Bioscience.
Hyundai Bioscience Tech Stack
A closer look at the technologies used by Hyundai Bioscience
Hyundai Bioscience News & Media
Hyundai Bioscience: "Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread"
SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus. Hyundai...Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this...Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-virus treatment, 2026 may mark the inaugural year of modern treatments that can treat multiple viruses with one drug, perhaps even viruses that haven't hit usPenetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
Penetrium™ Achieves Historic Breakthrough Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy Presented at AACR 2025, Chicago CHICAGO, May 8, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combination preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held in Chicago. The studies established that the repeated failures of immunotherapy and antibody treatments in col
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Hyundai Bioscience
Sign Up For FreeTo access detailed company insights
HYUNDAI BIOSCIENCE is a specialized biotechnology company focused on drug delivery system (DDS) technologies. They offer innovative and efficient solutions based on accumulated research and advanced bio-technology, targeting various medical conditions including cancer and viral infections. Their product lineup includes XAFTY, a broad-spectrum antiv... Read More
